troglitazone has been researched along with Cancer of Cervix in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HM | 1 |
| Zhang, DG | 1 |
| Wu, JX | 1 |
| Pei, DS | 1 |
| Zheng, JN | 1 |
| Chang, HK | 1 |
| Kim, DS | 1 |
| Chae, JJ | 1 |
| Kim, M | 1 |
| Myong, JP | 1 |
| Lee, KH | 1 |
| Lee, MW | 1 |
| Park, TC | 1 |
2 other studies available for troglitazone and Cancer of Cervix
| Article | Year |
|---|---|
Ubiquitination of p53 is involved in troglitazone induced apoptosis in cervical cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Fe | 2014 |
Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Caspase 3; Cell Survival; Cervix Uteri; Chromans; Drug | 2017 |